Search Result
Results for "
hypolipidemic
" in MedChemExpress (MCE) Product Catalog:
5
Isotope-Labeled Compounds
Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-34781
-
-
-
- HY-121776
-
|
Others
|
Cardiovascular Disease
|
Nicomol is an orally active hypolipidemic agent that can increase the high density lipoprotein cholesterol (HDL-C) level. Nicomol inhibits the rapid rise of plasma free fatty acids .
|
-
-
- HY-N1214S
-
Super Squalene-d6; trans-Squalene-d6; AddaVax-d6
|
Isotope-Labeled Compounds
|
Others
|
Squalene-d6 is a deuterium labeled Squalene. Squalene (Super Squalene) is an intermediate product in the synthesis of cholesterol, and shows several pharmacological properties such as hypolipidemic, hepatoprotective, antiatherosclerotic, cardioprotective, antioxidant, and antitumour activity .
|
-
-
- HY-119964
-
|
Others
|
Cardiovascular Disease
|
Cetaben is a PPARα-independent peroxisome proliferator. Cetaben is a non-fibrate hypolipidemic agent and potently reduces the concentration of cholesterol and triglycerides .
|
-
-
- HY-N6642
-
|
PPAR
Apoptosis
|
Inflammation/Immunology
Cancer
|
Ankaflavin, isolated from Monascus-Fermented red rice, is an orally active PPARγ agonist. Ankaflavin exhibits selective cytotoxic effect and induces cell death through apoptosis on cancer cells. Ankaflavin has anti-inflammatory, anti-cancer, antiatherosclerotic, and hypolipidemic effects .
|
-
-
- HY-116699
-
|
PPAR
|
Neurological Disease
Metabolic Disease
Inflammation/Immunology
|
CP-868388 free base is a potent, selective and orally active PPARα agonist with a Ki value of 10.8 nM. CP-868388 free base has little or no affinity for PPARβ (Ki of 3.47 μM) and PPARγ. CP-868388 free base has hypolipidemic and anti-inflammatory actions .
|
-
-
- HY-147246
-
HTD1801; BUDCA
|
Others
|
Metabolic Disease
|
Berberine ursodeoxycholate (HTD1801), an ionic salt of Berberine and Ursodeoxycholic acid, is an orally active and potent hypolipidemic agent. Berberine ursodeoxycholate shows significantly great reduction in liver fat content. Berberine ursodeoxycholate has a broad spectrum of metabolic activity. Berberine ursodeoxycholate can be used for the research of hyperlipidemia, non-alcoholic steatohepatitis (NASH) and diabetes .
|
-
-
- HY-137318
-
|
Others
|
Metabolic Disease
|
BM 15766 sulfate is an inhibitor of 7-dehydrocholesterol δ7-reductase and reduces plasma cholesterol levels. BM 15766 sulfate is a hypolipidemic agent .
|
-
-
- HY-125716
-
|
PPAR
|
Metabolic Disease
|
DRF-2519 (free base) is a dual activator of PPAR α and PPAR γ. DRF-2519 (free base) has antidiabetic and hypolipidemic activity .
|
-
-
- HY-121755
-
CP 18524
|
Others
|
Metabolic Disease
|
Tibric acid (CP 18524) has similar effects to those of hypolipidemic agents. Tibric acid has orally active triglyceride-lowering effects. Tibric acid can be used for research of hypertriglyceridemia .
|
-
-
- HY-N0652
-
2,3,4',5-Tetrahydroxystilbene 2-O-D-glucoside
|
ERK
NF-κB
|
Cardiovascular Disease
Neurological Disease
|
2,3,5,4'-Tetrahydroxystilbene 2-O-β-D-glucoside isolats from the roots of Polygonaceae species, inhibits the formation of 5-HETE, HHT and thromboxane B2. 2,3,5,4'-Tetrahydroxystilbene 2-O-β-D-glucoside has hypotensive, anti-ageing, anti-inflammatory, hypolipidemic, cardioprotective, and neuroprotective actions .
|
-
-
- HY-115914
-
|
Others
|
Others
|
Lipid-lowering agent-1 is a potent lipid-lowering agent. Lipid-lowering agent-1 has significant pharmacological effects on the inhibition of low-density lipoprotein cholesterol (LDLC) and promotion of high-density lipoprotein cholesterol (HDLC) production. Lipid-lowering agent-1 shows potent hypolipidemic effect in high-fat diet rats .
|
-
-
- HY-100144
-
-
-
- HY-19030
-
-
-
- HY-100334
-
-
-
- HY-100258
-
-
-
- HY-N0652R
-
|
ERK
NF-κB
|
Cardiovascular Disease
Neurological Disease
|
2,3,5,4'-Tetrahydroxystilbene 2-O-β-D-glucoside (Standard) is the analytical standard of 2,3,5,4'-Tetrahydroxystilbene 2-O-β-D-glucoside. This product is intended for research and analytical applications. 2,3,5,4'-Tetrahydroxystilbene 2-O-β-D-glucoside isolats from the roots of Polygonaceae species, inhibits the formation of 5-HETE, HHT and thromboxane B2. 2,3,5,4'-Tetrahydroxystilbene 2-O-β-D-glucoside has hypotensive, anti-ageing, anti-inflammatory, hypolipidemic, cardioprotective, and neuroprotective actions .
|
-
-
- HY-N8206
-
-
-
- HY-125780
-
-
-
- HY-113873
-
|
Others
|
Metabolic Disease
|
10-Thiastearic acid inhibits desaturation of? stearate to oleate. 10-Thiastearic acid has hypolipidemic effect .
|
-
-
- HY-N9725
-
16ξ-Hydroxycleroda-3,13-dien-15,16-olide
|
Dipeptidyl Peptidase
|
Metabolic Disease
|
16-Hydroxycleroda-3,13-dien-15,16-olide (16ξ-Hydroxycleroda-3,13-dien-15,16-olide; HCD), a clerodane diterpene, is a potent serine protease dipeptidyl peptidase 4 (DPP-4) inhibitor. 16-Hydroxycleroda-3,13-dien-15,16-olide down-regulates LPS-induced ERK phosphorylation in myocyte but blocks GLP-1 induced PKA expression. 16-Hydroxycleroda-3,13-dien-15,16-olide exhibits hypolipidemic, hepatoprotective, hypoglycemic efficacy .
|
-
-
- HY-A0127
-
|
Others
|
Metabolic Disease
|
Etofibrate is the ethandiol-1,2 diester of the nicotinic and clofibric acids. Etofibrate has been shown to be a potent hypolipidemic agent in animal and human.
|
-
-
- HY-124560
-
|
Others
|
Metabolic Disease
|
Lifibrol is a potent and oral activity hypolipidemic agent. Lifibrol decreases the plasma total cholesterol. Lifibrol has the potential for the research of hypercholesterolemia .
|
-
-
- HY-N1214
-
-
-
- HY-B1415
-
Chlorofibrinic acid
|
PPAR
Drug Metabolite
|
Others
|
Clofibric acid (Chlorofibrinic acid), the pharmaceutically active metabolite of lipid regulators Clofibrate, Etofibrate and Etofyllinclofibrate, is a PPARα agonist which exhibits hypolipidemic effects. Clofibric acid also is an herbicide .
|
-
-
- HY-105008
-
(S,S)-SDG; (S,S)-LGM2605
|
Others
|
Cardiovascular Disease
Neurological Disease
Inflammation/Immunology
|
Secoisolariciresinol diglucoside ((S,S)-SDG), the main lignan in wholegrain flaxseed, is known for its beneficial effects including anti-inflammatory, antioxidant, anti-mutagenic, anti-microbial, anti-obesity, hypolipidemic, and neuroprotective effects .
|
-
-
- HY-117549
-
NO-1886
|
Others
|
Cardiovascular Disease
|
Ibrolipim (NO-1886) is an orally active lipoprotein lipase (LPL)-promoting agent. Ibrolipim decreases plasma triglycerides, increases high-density lipoprotein cholesterol levels. Ibrolipim has renoprotective and hypolipidemic effects .
|
-
-
- HY-N7729
-
|
Amylases
Glucosidase
|
Metabolic Disease
|
Sekikaic acid is an α-glucosidase (Glucosidase) and α-amylase (Amylases) inhibitor with hypolipidemic, antioxidant and antidiabetic activities. Sekikaic acid significantly reduces LDL, total cholesterol, and total glyceride levels and causes pancreatic beta cell regeneration .
|
-
-
- HY-W012946
-
-
-
- HY-N1214R
-
|
Endogenous Metabolite
Reactive Oxygen Species
Fungal
|
Infection
Cardiovascular Disease
|
Squalene (Standard) is the analytical standard of Squalene. This product is intended for research and analytical applications. Squalene (Super Squalene) is an intermediate product in the synthesis of cholesterol, and shows several pharmacological properties such as hypolipidemic, hepatoprotective, antiatherosclerotic, cardioprotective, antioxidant, and antitumour activity .
|
-
-
- HY-N0807R
-
|
MMP
NF-κB
JAK
Keap1-Nrf2
|
Metabolic Disease
Inflammation/Immunology
Cancer
|
Swertiamarin (Standard) is the analytical standard of Swertiamarin. This product is intended for research and analytical applications. Swertiamarin is an orally active iridoid compound with hypoglycemic, hypolipidemic, anti rheumatic and antioxidant activities, which can be used in the research of diabetes and arthritis .
|
-
-
- HY-B1415S
-
Chlorofibrinic acid-d4
|
PPAR
Drug Metabolite
|
Others
|
Clofibric acid-d4 is the deuterium labeled Clofibric acid. Clofibric acid (Chlorofibrinic acid), the pharmaceutically active metabolite of lipid regulators Clofibrate, Etofibrate and Etofyllinclofibrate, is a PPARα agonist which exhibits hypolipidemic effects. Clofibric acid also is an herbicide[1][2][3].
|
-
-
- HY-14739
-
ABT-335
|
PPAR
COX
|
Cardiovascular Disease
|
Choline Fenofibrate (ABT-335), a choline salt of Fenofibric acid (HY-B0760), releases free Fenofibric acid in the gastrointestinal tract. Fenofibric acid is a PPAR activator with antihyperlipidemic effect .
|
-
-
- HY-14739R
-
|
PPAR
COX
|
Cardiovascular Disease
|
Choline Fenofibrate (Standard) is the analytical standard of Choline Fenofibrate. This product is intended for research and analytical applications. Choline Fenofibrate (ABT-335), a choline salt of Fenofibric acid (HY-B0760), releases free Fenofibric acid in the gastrointestinal tract. Fenofibric acid is a PPAR activator with antihyperlipidemic effect .
|
-
-
- HY-N6993
-
|
Others
|
Metabolic Disease
|
25-O-Methylalisol A is a protostane triterpenoids isolated from Alisma orientale. The dried rhizomes of the aquatic plant Alisma orientale known as Rhizoma Alismatis is a common traditional Chinese medicine used for diuretic, anti-inflammatory, and hypolipidemic purposes, as well as the treatment of diabetes .
|
-
-
- HY-B1415R
-
Chlorofibrinic acid (Standard)
|
PPAR
Drug Metabolite
|
Others
|
Clofibric acid (Standard) is the analytical standard of Clofibric acid. This product is intended for research and analytical applications. Clofibric acid (Chlorofibrinic acid), the pharmaceutically active metabolite of lipid regulators Clofibrate, Etofibrate and Etofyllinclofibrate, is a PPARα agonist which exhibits hypolipidemic effects. Clofibric acid also is an herbicide .
|
-
-
- HY-B0637
-
Bezafibrate
Maximum Cited Publications
7 Publications Verification
BM15075
|
PPAR
|
Cardiovascular Disease
Metabolic Disease
|
Bezafibrate is an agonist of PPAR, with EC50s of 50 μM, 60 μM, 20 μM for human PPARα, PPARγ and PPARδ, and 90 μM, 55 μM, 110 μM for murine PPARα, PPARγ and PPARδ, respectively; Bezafibrate is used as an hypolipidemic agent.
|
-
-
- HY-167664
-
|
Acyltransferase
|
Metabolic Disease
|
KY-455 is a novel inhibitor of acyl-CoA:cholesterol acyltransferase (ACAT). KY-455 inhibita rabbit intestinal, hepatic, macrophage and adrenal ACAT with IC50 values of 0.4, 0.9, 2.9 and 4.1 μmol/L, respectively.
|
-
-
- HY-B0637S
-
|
PPAR
|
Cardiovascular Disease
Metabolic Disease
|
Bezafibrate-d6 is the deuterium labeled Bezafibrate. Bezafibrate is an agonist of PPAR, with EC50s of 50 μM, 60 μM, 20 μM for human PPARα, PPARγ and PPARδ, and 90 μM, 55 μM, 110 μM for murine PPARα, PPARγ and PPARδ, respectively; Bezafibrate is used as an hypolipidemic agent.
|
-
-
- HY-B0637S1
-
BM15075-d4
|
Isotope-Labeled Compounds
PPAR
|
Cardiovascular Disease
Metabolic Disease
|
Bezafibrate-d4 is deuterium labeled Bezafibrate. Bezafibrate is an agonist of PPAR, with EC50s of 50 μM, 60 μM, 20 μM for human PPARα, PPARγ and PPARδ, and 90 μM, 55 μM, 110 μM for murine PPARα, PPARγ and PPARδ, respectively; Bezafibrate is used as an hypolipidemic agent.
|
-
-
- HY-W012946R
-
|
ATP Citrate Lyase
Acyltransferase
Endogenous Metabolite
|
Metabolic Disease
|
2-Furoic acid (Standard) is the analytical standard of 2-Furoic acid. This product is intended for research and analytical applications. 2-Furoic acid (Furan-2-carboxylic acid) is an organic compound produced through furfural oxidation . 2-Furoic acid exhibits hypolipidemic effet, lowers both serum cholesterol and serum triglyceride levels in rats .
|
-
-
- HY-W012946S
-
|
Acyltransferase
ATP Citrate Lyase
Endogenous Metabolite
|
Metabolic Disease
|
2-Furoic acid-d3 is the deuterium labeled 2-Furoic acid[1]. 2-Furoic acid (Furan-2-carboxylic acid) is an organic compound produced through furfural oxidation[2]. 2-Furoic acid exhibits hypolipidemic effet, lowers both serum cholesterol and serum triglyceride levels in rats[3].
|
-
-
- HY-B0637R
-
|
PPAR
|
Cardiovascular Disease
Metabolic Disease
|
Bezafibrate (Standard) is the analytical standard of Bezafibrate. This product is intended for research and analytical applications. Bezafibrate is an agonist of PPAR, with EC50s of 50 μM, 60 μM, 20 μM for human PPARα, PPARγ and PPARδ, and 90 μM, 55 μM, 110 μM for murine PPARα, PPARγ and PPARδ, respectively; Bezafibrate is used as an hypolipidemic agent.
|
-
-
- HY-N1934
-
|
Potassium Channel
HSP
|
Cardiovascular Disease
Inflammation/Immunology
Cancer
|
Dihydroberberine is a naturally occurring isoquinoline alkaloid with anti-inflammatory, anti-atherosclerotic, hypolipidemic and anti-tumor activities. Dihydroberberine inhibits the human ether-related gene (hERG) channel and significantly reduces the expression of heat shock protein 90 (Hsp90) and its interaction with hERG. Dihydroberberine also blocks the TLR4/MyD88/NF-κB signaling pathway to reduce pro-inflammatory cytokines and immunoglobulins, and has inhibitory effects on DSS (HY-116282C)-induced experimental colitis. Dihydroberberine also increases the sensitivity of lung cancer to sunitinib (HY-10255A), with synergistic efficacy .
|
-
-
- HY-137390A
-
|
Others
|
Cardiovascular Disease
Metabolic Disease
|
(3S,5R)-Fluvastatin (potassium) is a synthetic hypolipidemic drug that inhibits HMG-CoA reductase activity. (3S,5R)-Fluvastatin (potassium) has similar antioxidative effects on copper ion-induced LDL oxidation compared to its 3R,5S enantiomer. (3S,5R)-Fluvastatin (potassium) and its metabolites demonstrate a potential to exhibit anti-atherosclerotic effects through their antioxidative activities. (3S,5R)-Fluvastatin (potassium) is clinically utilized as part of a racemic mixture for reducing plasma cholesterol levels.
|
-
-
- HY-N1934R
-
|
Potassium Channel
HSP
|
Cardiovascular Disease
Inflammation/Immunology
Cancer
|
Dihydroberberine (Standard) is the analytical standard of Dihydroberberine. This product is intended for research and analytical applications. Dihydroberberine is a naturally occurring isoquinoline alkaloid with anti-inflammatory, anti-atherosclerotic, hypolipidemic and anti-tumor activities. Dihydroberberine inhibits the human ether-related gene (hERG) channel and significantly reduces the expression of heat shock protein 90 (Hsp90) and its interaction with hERG. Dihydroberberine also blocks the TLR4/MyD88/NF-κB signaling pathway to reduce pro-inflammatory cytokines and immunoglobulins, and has inhibitory effects on DSS (HY-116282C)-induced experimental colitis. Dihydroberberine also increases the sensitivity of lung cancer to sunitinib (HY-10255A), with synergistic efficacy .
|
-
Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
-
- HY-N6642
-
-
-
- HY-N0652
-
2,3,4',5-Tetrahydroxystilbene 2-O-D-glucoside
|
Structural Classification
Stilbenes
Classification of Application Fields
Polygonaceae
Source classification
Other Diseases
Phenols
Polyphenols
Fallopia multiflora (Thunb.) Harald.
Plants
Disease Research Fields
|
ERK
NF-κB
|
2,3,5,4'-Tetrahydroxystilbene 2-O-β-D-glucoside isolats from the roots of Polygonaceae species, inhibits the formation of 5-HETE, HHT and thromboxane B2. 2,3,5,4'-Tetrahydroxystilbene 2-O-β-D-glucoside has hypotensive, anti-ageing, anti-inflammatory, hypolipidemic, cardioprotective, and neuroprotective actions .
|
-
-
- HY-N8206
-
-
-
- HY-125780
-
-
-
- HY-N1214
-
-
-
- HY-105008
-
(S,S)-SDG; (S,S)-LGM2605
|
Cardiovascular Disease
Classification of Application Fields
Neurological Disease
Source classification
Lignans
Plants
Linum usitatissimum Linn.
Microorganisms
Linaceae
Phenols
Polyphenols
Phenylpropanoids
Disease Research Fields
|
Others
|
Secoisolariciresinol diglucoside ((S,S)-SDG), the main lignan in wholegrain flaxseed, is known for its beneficial effects including anti-inflammatory, antioxidant, anti-mutagenic, anti-microbial, anti-obesity, hypolipidemic, and neuroprotective effects .
|
-
-
- HY-W012946
-
-
-
- HY-N0652R
-
|
Structural Classification
Stilbenes
Polygonaceae
Source classification
Phenols
Polyphenols
Fallopia multiflora (Thunb.) Harald.
Plants
|
ERK
NF-κB
|
2,3,5,4'-Tetrahydroxystilbene 2-O-β-D-glucoside (Standard) is the analytical standard of 2,3,5,4'-Tetrahydroxystilbene 2-O-β-D-glucoside. This product is intended for research and analytical applications. 2,3,5,4'-Tetrahydroxystilbene 2-O-β-D-glucoside isolats from the roots of Polygonaceae species, inhibits the formation of 5-HETE, HHT and thromboxane B2. 2,3,5,4'-Tetrahydroxystilbene 2-O-β-D-glucoside has hypotensive, anti-ageing, anti-inflammatory, hypolipidemic, cardioprotective, and neuroprotective actions .
|
-
-
- HY-N7729
-
-
-
- HY-N1214R
-
-
-
- HY-N0807R
-
-
-
- HY-N6993
-
-
-
- HY-W012946R
-
-
-
- HY-N1934
-
-
-
- HY-N1934R
-
|
Alkaloids
Structural Classification
other families
Source classification
Plants
Isoquinoline Alkaloids
|
Potassium Channel
HSP
|
Dihydroberberine (Standard) is the analytical standard of Dihydroberberine. This product is intended for research and analytical applications. Dihydroberberine is a naturally occurring isoquinoline alkaloid with anti-inflammatory, anti-atherosclerotic, hypolipidemic and anti-tumor activities. Dihydroberberine inhibits the human ether-related gene (hERG) channel and significantly reduces the expression of heat shock protein 90 (Hsp90) and its interaction with hERG. Dihydroberberine also blocks the TLR4/MyD88/NF-κB signaling pathway to reduce pro-inflammatory cytokines and immunoglobulins, and has inhibitory effects on DSS (HY-116282C)-induced experimental colitis. Dihydroberberine also increases the sensitivity of lung cancer to sunitinib (HY-10255A), with synergistic efficacy .
|
-
Cat. No. |
Product Name |
Chemical Structure |
-
- HY-N1214S
-
|
Squalene-d6 is a deuterium labeled Squalene. Squalene (Super Squalene) is an intermediate product in the synthesis of cholesterol, and shows several pharmacological properties such as hypolipidemic, hepatoprotective, antiatherosclerotic, cardioprotective, antioxidant, and antitumour activity .
|
-
-
- HY-B0637S
-
|
Bezafibrate-d6 is the deuterium labeled Bezafibrate. Bezafibrate is an agonist of PPAR, with EC50s of 50 μM, 60 μM, 20 μM for human PPARα, PPARγ and PPARδ, and 90 μM, 55 μM, 110 μM for murine PPARα, PPARγ and PPARδ, respectively; Bezafibrate is used as an hypolipidemic agent.
|
-
-
- HY-B1415S
-
|
Clofibric acid-d4 is the deuterium labeled Clofibric acid. Clofibric acid (Chlorofibrinic acid), the pharmaceutically active metabolite of lipid regulators Clofibrate, Etofibrate and Etofyllinclofibrate, is a PPARα agonist which exhibits hypolipidemic effects. Clofibric acid also is an herbicide[1][2][3].
|
-
-
- HY-B0637S1
-
|
Bezafibrate-d4 is deuterium labeled Bezafibrate. Bezafibrate is an agonist of PPAR, with EC50s of 50 μM, 60 μM, 20 μM for human PPARα, PPARγ and PPARδ, and 90 μM, 55 μM, 110 μM for murine PPARα, PPARγ and PPARδ, respectively; Bezafibrate is used as an hypolipidemic agent.
|
-
-
- HY-W012946S
-
|
2-Furoic acid-d3 is the deuterium labeled 2-Furoic acid[1]. 2-Furoic acid (Furan-2-carboxylic acid) is an organic compound produced through furfural oxidation[2]. 2-Furoic acid exhibits hypolipidemic effet, lowers both serum cholesterol and serum triglyceride levels in rats[3].
|
-
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent: